• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Lupin launches Leflunomide Tablets USP

expresspharmaSeptember 03, 2020

Tag: lupin , Leflunomide Tablets USP , FDA , Rheumatoid Arthritis

Lupin announced the launch of Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (US FDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit I) facility in India.

Leflunomide Tablets USP, 10 mg and 20 mg, is the generic equivalent of Arava Tablets, 10 mg and 20 mg, of Sanofi-Aventis US, and is indicated for the treatment of adults with active rheumatoid arthritis (RA).

Leflunomide Tablets USP (RLD: Arava) had an annual sales of approximately USD 42 million in the U.S. (IQVIA MAT June 2020).


Previous:Abbott gets DCGI approval for Ivabradine

Next:BiomX collaborates with Boehringer Ingelheim for microbiome-based biomarkers for IBD

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin launches Leflunomide Tablets USP | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Fluorfenicol( FDA)

Fluorfenicol( FDA)
Irinotecan (FDA)

Irinotecan (FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)
Deltamine (FDA)

Deltamine (FDA)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Sirolimus (FDA)

Sirolimus (FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Ramantadine( FDA)

Ramantadine( FDA)
Etoposide( FDA)

Etoposide( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service